Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models

Journal of Inherited Metabolic Disease

Volumn 37, Issue 5, 2014, Pages 813-821

  Kingma, Sandra D K ^a   Wagemans, Tom ^a   IJlst, Lodewijk ^a   Wijburg, Frits A ^a,b   van Vlies, Naomi ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GENISTEIN; GLYCOSAMINOGLYCAN; ISOFLAVONE DERIVATIVE; SULFATE;

CARTILAGE CELL; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HUMAN; HURLER SYNDROME; METABOLISM; OSTEOBLAST;

CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CHONDROCYTES; ENZYME INHIBITORS; GENISTEIN; GLYCOSAMINOGLYCANS; HUMANS; ISOFLAVONES; MUCOPOLYSACCHARIDOSIS I; OSTEOBLASTS; SULFATES;

EID: 84897353019     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9703-x     Document Type: Article

References (37)

1. Akiyama T, Ishida J, Nakagawa S et al (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592–5595
2. Aldenhoven M, Boelens JJ, de Koning TJ (2008) The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 14:485–498
3. Arfi A, Richard M, Gandolphe C, Scherman D (2010) Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J Inherit Metab Dis 33:61–67
4. Baldo G, Mayer FQ, Martinelli BZ et al (2013) Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab 109:33–40
5. Blunk T, Sieminski AL, Gooch KJ et al (2002) Differential effects of growth factors on tissue-engineered cartilage. Tissue Eng 8:73–84
6. Blunk T, Sieminski AL, Appel B et al (2003) Bone morphogenetic protein 9: a potent modulator of cartilage development in vitro. Growth Factors 21:71–77
7. Coldham NG, Sauer MJ (2000) Pharmacokinetics of [(14)C]Genistein in the rat: gender-related differences, potential mechanisms of biological action, and implications for human health. Toxicol Appl Pharmacol 164:206–215
8. de Ruijter J, Valstar MJ, Narajczyk M et al (2012) Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 71:110–120
9. Delgadillo V, O’Callaghan MM, Artuch R, Montero R, Pineda M (2011) Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 34:1039–1044
10. Ferdinandusse S, Denis S, Dacremont G, Wanders RJ (2009) Toxicity of peroxisomal C27-bile acid intermediates. Mol Genet Metab 96:121–128
11. Gooch KJ, Blunk T, Courter DL, Sieminski AL, Vunjak-Novakovic G, Freed LE (2002) Bone morphogenetic proteins-2, -12, and -13 modulate in vitro development of engineered cartilage. Tissue Eng 8:591–601
12. Hiraki Y, Inoue H, Hirai R, Kato Y, Suzuki F (1988) Effect of transforming growth factor beta on cell proliferation and glycosaminoglycan synthesis by rabbit growth-plate chondrocytes in culture. Biochim Biophys Acta 969:91–99
13. Hwang KA, Park MA, Kang NH et al (2013) Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 beta-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor alpha and insulin-like growth factor-1 receptor signaling pathways. Toxicol Appl Pharmacol 272:637–646
14. Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, Baranska S, Wegrzyn G (2009) Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16:26
15. Junker JP, Sommar P, Skog M, Johnson H, Kratz G (2010) Adipogenic, chondrogenic and osteogenic differentiation of clonally derived human dermal fibroblasts. Cells Tissues Organs 191:105–118
16. Kim H, Xu J, Su Y et al (2001) Actions of the soy phytoestrogen genistein in models of human chronic disease: potential involvement of transforming growth factor beta. Biochem Soc Trans 29:216–222
17. Kim KH, Dodsworth C, Paras A, Burton BK (2013) High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol Genet Metab 109:382–385
18. Kingma SD, Langereis EJ, De Klerk CM et al (2013) An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life. Orphanet J Rare Dis 8:99
19. Kloska A, Jakobkiewicz-Banecka J, Narajczyk M, Banecka-Majkutewicz Z, Wegrzyn G (2011) Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab Brain Dis 26:1–8
20. Kloska A, Narajczyk M, Jakobkiewicz-Banecka J et al (2012) Synthetic genistein derivatives as modulators of glycosaminoglycan storage. J Transl Med 10:153
21. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W (2002) Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 30:215–222
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
23. Mackie EJ, Tatarczuch L, Mirams M (2011) The skeleton: a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification. J Endocrinol 211:109–121
24. Malinova V, Wegrzyn G, Narajczyk M (2012) The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients. JIMD Rep 5:21–25
25. Malinowska M, Wilkinson FL, Langford-Smith KJ et al (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 5:e14192
26. Muenzer J (2011) Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 50(Suppl 5):v4–12
27. Oussoren E, Brands MM, Ruijter GJ, der Ploeg AT, Reuser AJ (2011) Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim Biophys Acta 1812:1542–1556
28. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S et al (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14:846–852
29. Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A et al (2011) Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 17:CR196–CR202
30. Ramakers C, Ruijter JM, Deprez RH, Moorman AF (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339:62–66
31. Sifuentes M, Doroshow R, Hoft R et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90:171–180
32. Simonaro CM, D’Angelo M, He X et al (2008) Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 172:112–122
33. Tirone E, D’Alessandris C, Hascall VC, Siracusa G, Salustri A (1997) Hyaluronan synthesis by mouse cumulus cells is regulated by interactions between follicle-stimulating hormone (or epidermal growth factor) and a soluble oocyte factor (or transforming growth factor beta1). J Biol Chem 272:4787–4794
34. van der Linden MH, Kruyt MC, Sakkers RJ, de Koning TJ, Oner FC, Castelein RM (2011) Orthopaedic management of Hurler’s disease after hematopoietic stem cell transplantation: a systematic review. J Inherit Metab Dis 34:657–669
35. Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S (2004) Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 24:97–101
36. White KK (2011) Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 50(Suppl 5):v26–v33
37. Yuan WJ, Jia FY, Meng JZ (2009) Effects of genistein on secretion of extracellular matrix components and transforming growth factor beta in high-glucose-cultured rat mesangial cells. J Artif Organs 12:242–246